British fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases.
US experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2
Scientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments.
Roche and Regeneron have signed an manufacturing and distribution agreement on Regenerons Phase II therapeutic antibody for the treatment of COVID-19.
Antinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.
Using data from more than 20,000 patients with neurological diseases, researchers have established an algorithm that predicts whether mutations in ion channels will cause disease.
UK-Austrian fungal infection specialist F2G Ltd has secured a 50.8m (US $60.8m) financing from new and existing investors.
Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.
BioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.